84 percent of patients had no ISUP Grade Group \u22652 prostate cancer at three-month treatment zone biopsies<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
TUESDAY, Feb. 3, 2026 (HealthDay News) — A novel, cooled laser focal therapy (cLFT) exhibits high treatment success for localized prostate cancer (PCa), according to a study published online Jan. 28 in BJU International<\/em>.<\/p>\n Jonathan Kam, M.D., from Nepean Hospital in Kingswood, Australia, and colleagues recruited men with localized PCa, T stage \u2264T2c, and an International Society of Urological Pathology (ISUP) score of 2 to 3, concordant with multiparametric magnetic resonance imaging (mpMRI)-visible disease to examine the short-term oncological results and safety of a novel cLFT, which was performed under general anesthesia as a day procedure. The adequacy of tissue ablation assessed by mpMRI within 72 hours and biopsy at three months was examined as the primary outcome.<\/p>\n One hundred patients were recruited for the trial (median age, 66 years; prostate-specific antigen level, 5.9 ng\/mL). The median treatment duration was 60 minutes. The researchers found that in their three-month treatment zone biopsies, 84 percent had no ISUP Grade Group \u22652 PCa. Twelve percent of men reported erectile dysfunction, with a 15 percent decrease seen in the Sexual Health Inventory for Men and Expanded Prostate cancer Index Composite (EPIC)-sexual domains scores. EPIC-urinary domain scores had a 4.5 percent decrease. No decline was seen in any other functional measures.<\/p>\n “This new technology is very promising with excellent cancer control while preserving patients’ quality of life,” Kam said in a statement. “With this new technology, patients can have their prostate cancer treated with very low risk of suffering the side effects associated with traditional prostate cancer treatments.”<\/p>\n Several authors disclosed ties to Medlogical Innovations, which provided the ProFocal device for this trial.<\/p>\n